Autolus Therapeutics Reports Officer/Director Changes, Comp. Arrangements

TL;DR

**Autolus Therapeutics just reported leadership changes and new compensation plans.**

AI Summary

Autolus Therapeutics plc filed an 8-K on January 10, 2024, reporting an event that occurred on January 9, 2024, related to the departure or election of directors or officers and their compensatory arrangements. The filing also included a Regulation FD Disclosure and information on financial statements and exhibits. This matters to investors because changes in leadership and executive compensation can signal shifts in company strategy or financial health, potentially impacting future stock performance.

Why It Matters

Changes in executive leadership and compensation can influence a company's strategic direction and operational efficiency, directly affecting investor confidence and stock valuation.

Risk Assessment

Risk Level: medium — Changes in leadership can introduce uncertainty, but the specific details of the changes and compensation are not provided in this summary, making the impact unclear.

Analyst Insight

Investors should monitor future filings or company announcements from Autolus Therapeutics plc for specific details on the reported leadership changes and compensation arrangements, as these will provide clearer insights into potential strategic shifts and their financial implications.

Key Numbers

• 2024-01-09 — Date of earliest event reported (The date the reported event, such as director changes, occurred.)
• 001-38547 — Commission File Number (Autolus Therapeutics plc's SEC file number.)
• 44 20 3829 6230 — Registrant's telephone number (Contact number for Autolus Therapeutics plc.)

Key Players & Entities

• Autolus Therapeutics plc (company) — the registrant filing the 8-K
• The Nasdaq Global Select Market (company) — exchange where Autolus's American Depositary Shares are registered
• $0.000042 (dollar_amount) — par value per ordinary share of Autolus Therapeutics plc

Forward-Looking Statements

• Further details regarding the specific director/officer changes and compensatory arrangements will be disclosed in subsequent filings or company announcements. (Autolus Therapeutics plc) — high confidence, target: 2024-03-31

FAQ

From the Filing

0001730463-24-000004.txt : 20240110 0001730463-24-000004.hdr.sgml : 20240110 20240110151217 ACCESSION NUMBER: 0001730463-24-000004 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240109 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240110 DATE AS OF CHANGE: 20240110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Autolus Therapeutics plc CENTRAL INDEX KEY: 0001730463 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38547 FILM NUMBER: 24526333 BUSINESS ADDRESS: STREET 1: THE MEDIAWORKS STREET 2: 191 WOOD LANE CITY: LONDON STATE: X0 ZIP: W12 7FP BUSINESS PHONE: 44 20 3829 6230 MAIL ADDRESS: STREET 1: THE MEDIAWORKS STREET 2: 191 WOOD LANE CITY: LONDON STATE: X0 ZIP: W12 7FP FORMER COMPANY: FORMER CONFORMED NAME: Autolus Therapeutics Ltd DATE OF NAME CHANGE: 20180205 8-K 1 autl-20240109.htm 8-K autl-20240109 0001730463 FALSE 0001730463 2024-01-09 2024-01-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2024 Autolus Therapeutics plc (Exact name of registrant as specified in its Charter) England and Wales 001-38547 Not applicable (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) The MediaWorks 191 Wood Lane London W12 7FP United Kingdom (Address of principal executive offices) (Zip Code) (44) 20 3829 6230 (Registrant's telephone number, including area code) Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered American Depositary Shares, each representing one ordinary share, par value $0.000042 per share AUTL The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of New Director On January 10, 2024, the Company announced that the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Robert (“Bob”) W. Azelby to serve as a Class II director of the Company, effective January 9, 2024. Mr. Azelby was appointed to serve as a member of the B